Spectral AI

Spectral AI, founded in 2009 and originally known as Spectral MD, develops predictive medical diagnostics for wound care. The company pairs multispectral imaging with artificial intelligence to produce objective assessments of a wound's healing potential - signals that are not visible to the naked eye and that would otherwise be judged by subjective visual inspection. It is headquartered in Dallas, Texas, and trades on Nasdaq under the ticker MDAI.

Its principal product, the DeepView™ System, combines proprietary multispectral imaging hardware with AI algorithms that output an immediate read on healing potential, supporting faster and more consistent treatment decisions from the point of patient admission. The burn indication of the DeepView System has received FDA De Novo clearance. The technical work spans multispectral imaging, medical imaging, machine learning, and wound-healing prediction algorithms, with applications in burn care and diabetic foot ulcers among other wound types.

The company was founded to address a clinical gap identified by physician-scientist Dr. J. Michael DiMaio, with a stated emphasis on replacing subjective assessment with data-driven clinical decision-making. Beyond commercial markets, Spectral AI holds contracts with BARDA, the Defense Health Agency, and the Department of Defense, reflecting activity in military medicine and government health agencies. Its stated direction is to expand wound care applications globally.